Inactivation of LARS2, located at the commonly deleted region 3p21.3, by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma

Acta Biochimica Et Biophysica Sinica
Wen ZhouCaiping Ren

Abstract

Allelic loss of chromosome 3p, including the 3p21.3 region, is found in 95-100% of primary nasopharyngeal carcinoma (NPC) biopsies, suggesting that this region should harbor some tumor suppressor genes (TSGs) closely related to NPC development. Several TSGs located at 3p21.3, such as RASSF1A, LTF and BLU, have been demonstrated to be involved in NPC development. LARS2 (leucyl-tRNA synthetase 2, mitochondrial) is another gene located in the chromosome 3 common eliminated region-1 (C3CER1) at 3p21.3. In this study, we focussed on the epigenetic and genetic alterations of LARS2 in NPC. The mRNA expression of LARS2 was detected in 36 NPC and 8 chronic nasopharyngitis (NP) tissues by semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) and real-time RT-PCR. Subsequently, the mutation, allelic loss, and methylation status of LARS2 were analysed by polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP), homozygous deletion (HD) analysis and methylation-specific polymerase chain reaction in primary NPC tissues. No expression or downregulation of LARS2 was observed in 78% of primary NPC tissues. No mutations, assessed by PCR-SSCP and DNA sequencing, were found in the promoter region and exon 1...Continue Reading

References

Jun 23, 2001·Neoplasia : an International Journal for Oncology Research·H W YangY Hayashi
Jan 30, 2004·International Journal of Cancer. Journal International Du Cancer·Hanna TuhkanenArto Mannermaa
Feb 18, 2004·Laboratory Investigation; a Journal of Technical Methods and Pathology·Robert StoehrArndt Hartmann
May 18, 2004·Cancer Cell·Kwok Wai LoDolly P Huang
Jun 10, 2004·Genes, Chromosomes & Cancer·Zhongxi HuangKaitai Yao
Jun 14, 2005·Lancet·William I Wei, Jonathan S T Sham
Oct 29, 2005·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Wensheng YanYan Fang
Feb 22, 2007·Current Molecular Medicine·Josephine S Modica-NapolitanoKeshav K Singh
May 5, 2007·Oncology Research·Hong-Mei YiCai-Ping Ren
May 26, 2007·Briefings in Functional Genomics & Proteomics·Debora Angeloni
May 30, 2007·Oncogene·L B HessonF Latif
Jun 29, 2007·Expert Reviews in Molecular Medicine·Tip W Loo, David M Clarke

❮ Previous
Next ❯

Citations

Jan 9, 2016·Asian Pacific Journal of Cancer Prevention : APJCP·Wei JiangQiu-Qiu Chen
Jun 19, 2012·Clinical Epigenetics·Semra Demokan, Nejat Dalay
Apr 17, 2015·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Sabina SevcikovaRoman Hajek
May 4, 2017·Oncotarget·Fatima Valdés-MoraJuan Carlos Lacal
Sep 24, 2011·Nature Reviews. Cancer·Sunghoon KimDaehee Hwang
Aug 8, 2021·International Journal of Molecular Sciences·Joseph E FriedlanderHui Feng
Jan 1, 2010·Journal of Experimental & Clinical Cancer Research : CR·Tao WangGang Wu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.